Best Plasmid DNA CDMOs in Europe
· updated as new inspection, certificate, and trial data enters the platform
11
CDMOs tracked
11
Fully scored
4
With FDA records
23
FDA inspections
102
EMA/MHRA GMP certs
2
Warning letters
Plasmid DNA is the upstream starting material for viral vectors, mRNA, and DNA therapeutics — which makes plasmid supply a frequent bottleneck for the entire advanced-therapy pipeline. Plasmid CDMOs run microbial (E. coli) fermentation, alkaline lysis, and chromatographic purification to GMP grade.
Selecting a plasmid CDMO turns on GMP vs research grade, supercoiled fraction and purity, fermentation scale, and lead time. The rankings below score each CDMO on FDA inspections, GMP certification, clinical activity, and capacity.
FDA inspection outcomes across these CDMOs: 8 NAI (no action), 13 VAI (voluntary action), 2 OAI (official action). Leading inspection & GMP sites: Germany (29), UNITED KINGDOM (23), United States (21), Austria (11), Belgium (11).
Last updated 2026-09-15. Sourced from FDA, EMA EudraGMDP, MHRA GMDP, and ClinicalTrials.gov.
| # | CDMO | Signal Score | Quality | FDA · GMP | Capacity | Programs |
|---|---|---|---|---|---|---|
| 1 |
OX
Oxford Biomedica
Oxford, United Kingdom
|
76.2 | 100.0 | 0 insp · 13 GMP | Available | 7 programs |
| 2 |
CR
Charles River Laboratories
Newbury Park, CA · Memphis, TN · Keele, UK · Rockville, MD
|
90.9 | 98.3 | 8 insp · 11 GMP | Limited | 0 programs |
| 3 |
RP
ReciBioPharm
Keele, UK · Sodertalje, SE
|
88.0 | 100.0 | 0 insp · 3 GMP | — | 0 programs |
| 4 |
RB
Richter BioLogics
Hamburg, Germany
|
82.9 | 100.0 | 0 insp · 9 GMP | — | 0 programs |
| 5 |
WK
Wacker Biotech
Jena, DE · Amsterdam, NL · San Diego, CA
|
81.6 | 100.0 | 0 insp · 13 GMP | — | 0 programs |
| 6 |
KE
Kaneka Eurogentec
Seraing, BE
|
80.3 | 100.0 | 0 insp · 4 GMP | — | 0 programs |
| 7 |
AA
Ascend Advanced Therapies
London, United Kingdom
|
78.1 | 100.0 | 0 insp · 1 GMP | — | 0 programs |
| 8 |
BM
Biomay AG
Vienna, Austria
|
76.3 | 98.9 | 2 insp · 11 GMP | — | 0 programs |
| 9 |
Catalent
Bagsværd, Denmark (operating under Novo Holdings; key US DP site: Bloomington, IN)
|
73.1 | 74.9 | 12 insp · 37 GMP | — | 0 programs |
| 10 |
CA
Catalent (Novo Holdings)
Harmans, MD · Gosselies, BE
|
73.1 | 74.9 | 1 insp · 0 GMP | Available | 0 programs |
| 11 |
PF
PlasmidFactory
Bielefeld, Germany
|
56.5 | — | — | — | 0 programs |
What to evaluate in a Plasmid DNA CDMO
GMP grade & purity
Confirm GMP (vs research/HQ) grade, supercoiled percentage, and residual host-cell DNA/RNA and endotoxin specs — these gate downstream vector and mRNA quality.
Fermentation scale & yield
Match fermentation scale and yield to your vector or mRNA demand. Ask about high-yield strains and whether scale-up is validated.
Lead time
Plasmid is a common critical-path bottleneck. Evaluate realistic queue and turnaround against your program timeline.
Regulatory track record
Cross-check FDA 483 history and EMA/MHRA GMP coverage — both shown above and on each profile.
EMA and MHRA regulatory considerations for European-manufactured programs
European manufacturing for biopharma programs typically requires EMA-recognized GMP certification (via the EudraGMDP database) for EU material and MHRA GMP certification for UK material — post-Brexit, these are separate credentials even for CDMOs operating in both. The Signal Score's Quality Compliance pillar weighs EMA + MHRA GMP certificate density directly, so European CDMOs with dense certification typically rank higher on this pillar. Sponsors should verify certificate coverage for the specific manufacturing activity (drug substance vs drug product, dosage form) at the specific facility being considered — GMP certificates are activity-scoped, not blanket.
QP release requirements and how they affect CDMO selection
Every batch of medicinal product supplied to the EU market must be released by a Qualified Person (QP) — a specific regulatory role with statutory responsibility. This adds a process step (and typically a specific QP-service arrangement) that US-only manufacturing does not require. CDMOs with European operations either have in-house QPs (typical for larger diversified players) or coordinate with external QP services. For sponsors running EU trials or supplying EU commercial markets, this is a non-negotiable requirement to plan for. Individual CDMO profile pages capture facility-level detail; QP arrangements specifically are usually confirmed at RFP stage rather than published.
Which European CDMOs also cover FDA (US) regulatory geography?
European CDMOs with US FDA inspection history — indicating US regulatory posture — are candidates for sponsors running programs in both jurisdictions. The Signal Score's Quality Compliance pillar includes FDA inspection classifications, so a European CDMO with a strong FDA record typically ranks higher on that pillar than a European-only competitor. Cross-check with the US region ranking — CDMOs appearing in both rankings have demonstrated regulatory posture across both jurisdictions, which reduces tech-transfer risk for global programs.
Plasmid DNA CDMOs — Frequently Asked Questions
Who are the top Plasmid DNA CDMOs?
By CDMO Signal's independent Signal Score, the top-ranked Plasmid DNA CDMOs include Oxford Biomedica, Charles River Laboratories, ReciBioPharm. See the full ranked table above — scored on FDA, clinical, financial, and capacity data.
How many Plasmid DNA CDMOs have FDA inspection records?
CDMO Signal tracks 4 Plasmid DNA CDMOs with FDA inspection records and 102 EMA/MHRA GMP certificates across the group.
What should I look for in a plasmid DNA CDMO?
Confirm GMP grade and purity specs (supercoiled %, residual host DNA, endotoxin), fermentation scale and yield for your demand, realistic lead time, and a clean FDA and EMA/MHRA record.
Why is plasmid DNA supply often a bottleneck?
Plasmid is the starting material for viral vectors and mRNA, so a single GMP plasmid lot gates multiple downstream steps. Constrained GMP fermentation capacity and long queues make it a frequent critical-path item.
Related modalities